During this year's Alzheimer's & Parkinson's Diseases Conference, AD/PD 2022, touchNEUROLOGY caught up with Dr Tim Bartels (UK Dementia Research Institute, University College London) to discuss some of the highlights in the field of new therapeutics for neurodegeneration, and also the presentation of functioning MRI agents for α-Synuclein. Watch the video, here: https://touchneurology.com/alzheimers-disease-dementia/conference-hub/tim-bartels-highlights-at-ad-pd-2022/
TouchNEUROLOGY also spoke to Prof. Huntington Potter (University of Colorado, Denver, USA) to discuss sargramostim, an innate immune system modulator which has been investigated in a phase 2 study to determine if it can safely halt or reduce cognitive decline and brain pathology in participants with mild-to-moderate Alzheimer’s disease (AD). The phase 2 results (NCT01409915) to investigate whether inflammation and the innate immune system in AD may provide therapeutic benefit, and what will be the next steps in the development of sargramostim in AD. Watch the video, here:
